Intravitreal ranibizumab injection as an adjuvant combined 23-gauge vitrectomy and ahmed glaucoma valve implantation in the treatment of neovascular glaucoma

Abstract

Objective To observe the effects of intravitreal Ranibizumab injection (IVR) as an Adjuvant combined 23-gauge vitrectomy (23G-TSV) and Ahmed glaucoma valve (AGV) implantation for Neovascular Glaucoma (NVG). Methods Twenty-five patients (25 eyes) of NVG with vitreous hemorrhage (VH) underwent IVR combined with 23G-TSV and AGV implantation. Results The neovascularization of iris and anterior chamber angle in all patients completely or partly disappeared one week after IVR. At last visit, BCVA was improved compared with pre-operative BCVA; the IOP was significantly decreased after surgery; The surgical success rate was 88.0%. No serious complication occurred. Conclusions For stage Ⅲ NVG with VH, IVR as an adjuvant combined 23G-TSV and AGV implantation is safe and effective. Key words: Glaucoma; Neovascular; Implants; Ahmed; Vitrectomy; 23G; Ranibizumab